Nadia Harbeck, MD, PhD, Ludwig Maximilian University of Munich, Munich, Germany, discusses the predicative impact of biomarkers on pathological complete response (pCR) and survival in patients HER2+/HR+ early breast cancer. In the WSG TP phase II-trial, part of the ADAPT umbrella (NCT01779206), 375 patients received trastuzumab emtansine with or without endocrine therapy (ET), or trastuzumab with ET. Tumor-infiltrating lymphocytes (TILs) were not predicative of invasive disease-free survival (iDFS), whereas tumor immunogenicity was associated with improved outcomes. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
Nadia Harbeck, MD, PhD, has received honoraria for lectures and/or consulting: Amgen, Astra Zeneca, Daiichi-Sankyo, Exact Sciences, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen Institution: Clinical phase II-IV trials Other: Co-Director West German Study Group (WSG)